Q1 Earnings Forecast for AQST Issued By HC Wainwright

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Aquestive Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.15) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.11) EPS.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million.

A number of other equities analysts have also issued reports on the stock. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital lowered their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Finally, Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $10.57.

Aquestive Therapeutics Stock Down 3.3 %

Shares of NASDAQ:AQST opened at $2.62 on Monday. Aquestive Therapeutics has a 52-week low of $2.24 and a 52-week high of $5.80. The stock has a market cap of $259.04 million, a price-to-earnings ratio of -5.82 and a beta of 2.59. The business has a 50-day moving average price of $2.96 and a 200-day moving average price of $3.85.

Hedge Funds Weigh In On Aquestive Therapeutics

Large investors have recently bought and sold shares of the business. Verition Fund Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $995,000. State Street Corp increased its holdings in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after acquiring an additional 512,682 shares in the last quarter. Harvey Capital Management Inc. raised its position in Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after acquiring an additional 249,790 shares during the period. Wellington Management Group LLP purchased a new position in Aquestive Therapeutics during the third quarter valued at $922,000. Finally, BNP Paribas Financial Markets grew its position in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after purchasing an additional 13,481 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.